Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from URGN

Short Sellers Are Betting Against UroGen Pharma Stock, But Wall Street Expects 263% Earnings Growth in 2027

UroGen Pharma (URGN) has surged nearly 180% over the past year and has strong technical momentum. URGN maintains a 100% “Buy” technical opinion from Barchart. The company’s revenue is projected to more than double this year and grow by 56% next year. Earnings are estimated to rise by 75% and...

Barchart · Jul 17

3 Bullish Biotech Stocks With Explosive Growth Trends

3 Bullish Biotech Stocks With Explosive Growth Trends

These small-cap biotech stocks offer high-reward potential with bullish momentum and key catalysts ahead in urology, autoimmune, and gene editing therapies

MarketBeat · Jul 21, 2025

3 Biotech Stocks Climbing the Ranks to Watch

3 Biotech Stocks Climbing the Ranks to Watch

The biotech industry is thriving on growing applications across sectors from healthcare to agriculture, favorable government funding and policies, and technological breakthroughs. Amid this backdrop, quality biotech stocks UroGen Pharma (URGN), Foghorn Therapeutics (FHTX), and Galapagos (GLPG) might be ideal additions to one’s watchlist. Read on….

StockNews.com · Mar 1, 2024

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

UroGen Pharma: Q1 Earnings Insights

UroGen Pharma (NASDAQ:URGN) reported its Q1 earnings results on Tuesday, May 10, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Benzinga · May 10, 2022

Earnings Outlook For UroGen Pharma

UroGen Pharma (NASDAQ:URGN) is set to give its latest quarterly earnings report on Tuesday, 2022-05-10. Here's what investors need to know before the announcement. Analysts estimate that UroGen Pharma will report an earnings per share (EPS) of $-1.33.

Benzinga · May 9, 2022

UroGen Pharma's Return On Capital Employed Overview

According to data from Benzinga Pro, during Q4, UroGen Pharma's (NASDAQ:URGN) reported sales totaled $16.17 million. Despite a 5.82% increase in earnings, the company posted a loss of $28.45 million.

Benzinga · Mar 22, 2022

Earnings Outlook For UroGen Pharma

UroGen Pharma (NASDAQ:URGN) is set to give its latest quarterly earnings report on Monday, 2022-03-21. Here's what investors need to know before the announcement. Analysts estimate that UroGen Pharma will report an earnings per share (EPS) of $-1.17.

Benzinga · Mar 18, 2022

inkl

Read news from The Economist, FT, and more,
with one subscription

UroGen Pharma Earnings Preview

UroGen Pharma Earnings Preview

UroGen Pharma (NASDAQ:URGN) is set to give its latest quarterly earnings report on Monday, 2022-03-21. Here's what investors need to know before the announcement. Analysts estimate that UroGen Pharma will report an earnings per share (EPS) of $-1.17.

Benzinga · Mar 18, 2022

UroGen Pharma Q4 2021 Earnings Conference Call On March 21, 2022 At 10:00 AM ET

UroGen Pharma Q4 2021 Earnings Conference Call On March 21, 2022 At 10:00 AM ET

UroGen Pharma (NASDAQ:URGN) will host a conference call at 10:00 AM ET on March 21, 2022, to discuss Q4 2021 earnings results. How to Attend UroGen Pharma (URGN) Conference Call Follow this link to access the live webcast.

Benzinga · Mar 17, 2022

Earnings Outlook For UroGen Pharma

Earnings Outlook For UroGen Pharma

UroGen Pharma (NASDAQ:URGN) is set to give its latest quarterly earnings report on Thursday, 2022-03-10. Here's what investors need to know before the announcement. Analysts estimate that UroGen Pharma will report an earnings per share (EPS) of $-1.17.

Benzinga · Mar 9, 2022

1

Coverage From

People

Kritika SarmahHer

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

421,028 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play